Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis.
about
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.Mindfulness-based cognitive therapy for inflammatory bowel disease patients: findings from an exploratory pilot randomised controlled trial.Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaireFirst multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory coursesAn optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity indexGut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitisSafety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study.Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire.A new look at a mainstay ulcerative colitis therapySignificance of low level infliximab in the absence of anti-infliximab antibodies.Fecal Calprotectin is an Accurate Tool and Correlated to Seo Index in Prediction of Relapse in Iranian Patients With Ulcerative Colitis.A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research.Colitis-induced neuroplasticity disrupts motility in the inflamed and post-inflamed colon.Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation.Safety and efficacy of Profermin® to induce remission in ulcerative colitis.Psychosocial factors contributing to inflammatory bowel disease activity and health-related quality of lifeAshkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure.Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases.Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn DiseaseAssessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative ColitisQuality of life of patients with ulcerative colitis: past, present, and future.Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature.Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remissionHistologic markers of inflammation in patients with ulcerative colitis in clinical remission.Patients' and clinicians' research prioritiesCost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.The Use of Complementary and Alternative Medicine among Patients with Inflammatory Bowel Disease Is Associated with Reduced Health-Related Quality of LifeNeuroplasticity and dysfunction after gastrointestinal inflammation.Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres.Cognitive behaviour therapy and objective assessments in chronic fatigue syndrome.Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study.Does Computerized Cognitive Behavioral Therapy Help People with Inflammatory Bowel Disease? A Randomized Controlled Trial.Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question.Health-related Quality of Life in Patients with Inflammatory Bowel Disease 20 Years After Diagnosis: Results from the IBSEN Study.Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study.Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis.Predictors of health-related quality of life and adherence in Crohn's disease and ulcerative colitis: implications for clinical management.Coping Strategies and Psychological Outcomes of Patients with Inflammatory Bowel Disease in the First 6 Months After Diagnosis.
P2860
Q30440147-AA72CC52-6810-4402-A3E4-8CC29A5BB836Q30662409-F4C42207-3358-454B-B023-B36AAB86972DQ33557634-B4A40B3D-0BC8-4EC9-B36A-ECF08A3084A9Q33834727-5BE7BBE6-8AEA-49BA-A058-BC666255DFD9Q33858229-4B1EC335-8C2E-4034-91FB-16EF572B56B0Q34065540-CCC41229-599F-4BE8-8EEE-B9800C5EE6F6Q34743223-6301216A-037E-4675-AF11-BB4CDAA10A36Q34749491-FD78FF43-EB6F-4CF2-9276-A9C68DD0E9DAQ34885576-1236C841-A83E-476A-8DF1-ECA289A5AC90Q34940520-7C9223D4-93FD-4286-A3FF-A48C7AF8694BQ35069511-80CA74D5-BEE2-4722-A06E-ED1F6E585EB4Q35157904-17FE361A-878C-4183-8986-CCAB6E95B17DQ35169255-8958BF62-1EFD-48AD-9368-8D021592C3CCQ35183955-328C8577-0796-4804-8436-90EE64DEA99FQ35891368-F99DE5AD-CD92-4C29-AD05-2D9516972ADDQ35904302-2600651F-1AC2-4C84-A2BD-50CEC6EE3AE3Q36002200-8A5DAA4D-826B-4476-B6D0-D31A447FE1E0Q36151324-1B533CA5-FE40-44CA-B779-82961EB2291BQ36372720-AC2FD9E3-7D5D-4C60-A43D-90CD591BCF71Q36838154-25750741-9C92-4367-B1CA-867DBF2C023BQ36947788-ABF6D14C-BD1F-4E65-AD74-A8B870747397Q36987080-2E81E78E-040C-42E4-BCE3-17823C963313Q37094598-30DBB6D1-0D46-40CB-ADDA-0F7A316133A8Q37111911-C39C1AC3-6E99-4DF2-A4B9-EF5AD0A28F1BQ37122161-6529F252-7A55-49AA-8DE3-045BDEE1A3E0Q37332759-845606D0-687C-4B06-877C-62F1F67A6486Q37393339-EF423761-3103-4059-A056-AC0322CE89CDQ37492485-68F1FD3E-83E3-4B47-A006-C234435A5842Q38227089-54B5029E-290E-431C-AA0B-BF70BC0711F0Q38608941-496A267F-D8BB-4CE1-8CFB-0F379D831822Q38642969-00BCA053-339D-4F9F-A0C2-9DB5C4F82F94Q38895063-F0398DB4-8A3C-4700-BF12-57D55AE3853BQ38965011-E6EB95BF-851E-4B3D-8925-B4F201A76970Q39269680-92B0B798-ED9F-4658-830C-63699454CDE6Q39749465-5DB187E4-CB9C-45C5-9D25-1F49C30A14C6Q39841706-6E9CA212-BE1D-4EF9-B60F-A3C333D4099EQ40473404-D69E0CE7-5ED6-40F8-9E23-FF09A1C14C03Q41128447-56B45BD4-8570-497A-A2D9-E2A26F802C1FQ41624232-603168D8-A96F-4F66-9370-95F4042F731AQ41650843-E6CD4668-E14A-4291-B60B-938AC0993902
P2860
Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Patient defined dichotomous en ...... ovement in ulcerative colitis.
@ast
Patient defined dichotomous en ...... ovement in ulcerative colitis.
@en
type
label
Patient defined dichotomous en ...... ovement in ulcerative colitis.
@ast
Patient defined dichotomous en ...... ovement in ulcerative colitis.
@en
prefLabel
Patient defined dichotomous en ...... ovement in ulcerative colitis.
@ast
Patient defined dichotomous en ...... ovement in ulcerative colitis.
@en
P2093
P2860
P356
P1433
P1476
Patient defined dichotomous en ...... ovement in ulcerative colitis.
@en
P2093
E M Zimmermann
M Schwartz
P D R Higgins
P2860
P304
P356
10.1136/GUT.2004.056358
P407
P577
2005-06-01T00:00:00Z